Additionally, treatment with specific agonists for SSTR1, SSTR2, and SSTR5, but not for SSTR3, significantly decreased the proliferation rate of GBM cells at different times (24–48-72 h) depending on the agonist (Fig. 4F), being the most effective SSTR2-agonist (32.6% reduction at 72 h), followed by SSTR5-agonist (22.4% reduction at 24 h), and SSTR1-agonist (13.9% reduction at 72 h) (Fig. 4F). Here, SSTR5 is linked to glioblastoma.